Invivyd is a biopharmaceutical company focused on the discovery, development and commercialization of differentiated products for the prevention and/or treatment of viral infectious disease. Co. is obtaining regulatory authorization or approval for its lead product candidate, VYD222, for the prevention and/or treatment of SARS-CoV-2 (COVID-19). VYD222 is an engineered version of adintrevimab, Co.'s investigational monoclonal antibody. Co. is developing a pipeline of product candidates which could be used in prevention or treatment of serious viral diseases, starting with COVID-19 and expanding into influenza and other high-need indications. The IVVD YTD return is shown above.
The YTD Return on the IVVD YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether IVVD YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the IVVD YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|